Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine Combinations vs Monotherapy in HIV-Infected Individuals
NCT00000838Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of lamivudine in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Efficacy of treatment regimens at 48 weeks, Safety of treatment regimens at 48 weeks and 1 more. Status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000838.